Dihydralazine sulfate 

Dihydralazine sulfate is an antihypertensive hydrazine derivative and also a low-potency genotoxic agent. Dihydralazine sulfate is a direct-acting mutagen with a mixed gene mutation mechanism, which induces DNA fragmentation in the lung, kidney and spleen of mice, and induces sister chromatid exchange in mouse bone marrow cells. Dihydralazine sulfate specifically kills DNA repair-deficient bacteria. Dihydralazine sulfate is a vasodilator and antihypertensive agent that reduces systemic vascular resistance, increases cardiac output and heart rate, thereby lowering blood pressure. Dihydralazine sulfate can be used in research related to hypertension and severe early-onset preeclampsia^[1][2].

Dihydralazine sulfate (1 mg per plate, up to 14 μmol; standard Ames test incubation period) acts as a low-potency direct-acting mutagen in Salmonella typhimurium strains TA100, TA97, TA1537, TA98, and TA1538^[1].
Dihydralazine sulfate (5 mg (17.4 μmol) per spot; 24 h) is preferentially lethal to DNA repair-deficient Escherichia coli strains CM871 and TM1080, but not to excision repair-deficient WP2uvrA, indicating it induces DNA damage repaired primarily by recA recombination and lexA post-replication repair pathways^[1].
Dihydralazine sulfate exhibits preferential lethality to DNA repair-deficient Escherichia coli strains WP67 and CM871, with MIC values of 12.5 μg for both strains without S-9 mix^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Dihydralazine sulfate (53-318 mg/kg; i.p.; single dose; daily for 5 successive days) exhibits weak in vivo genotoxicity in noninbred male Swiss mice, inducing statistically significant DNA fragmentation in lung, kidney, and spleen (but not liver) across multiple dose schedules^[1].
Dihydralazine sulfate (0.1-2 mg/kg; intravenous injection; single dose) inhibited hemorrhagic hypotension in rats with renal hypertension (RHR) and spontaneous hypertension (SHR) without a decrease in cerebral blood flow (CBF)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

288.28

C₈H₁₂N₆O₄S

7327-87-9

Solid

Off-white to light yellow

N/N=C(C1=C/2C=CC=C1)\NNC2=N/N.O=S(O)(O)=O

Room temperature in continental US; may vary elsewhere.

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

• [1]. de Flora S, et al. In vivo and in vitro genotoxicity of three antihypertensive hydrazine derivatives (hydralazine, dihydralazine, and endralazine). Environ Mutagen. 1982;4(5):605-19.  [Content Brief]

  [2]. Bolte AC, et al. Ketanserin versus dihydralazine in the management of severe early-onset preeclampsia: maternal outcome. Am J Obstet Gynecol. 1999 Feb;180(2 Pt 1):371-7.  [Content Brief]